Curing Incurable Diseases with Jeff Galvin of American Gene Technologies episode artwork

EPISODE · Mar 25, 2021 · 26 MIN

Curing Incurable Diseases with Jeff Galvin of American Gene Technologies

from From Lab to Launch by Qualio · host Jeff Galvin

What if incurable diseases like HIV, cancer, PKU, and epithelial solid tumors were completely curable? We're closer than you might think. Really close. In fact, Jeff Galvin and his team at American Gene Technologies™ (AGT) have been advancing the research and application of viral vectors for several years with some incredibly exciting breakthroughs on the horizon (hint: curing HIV could be just a few years away). In case you didn't know already, viral vectors is a relatively new technology where you can crack open any virus, scoop out the malevolent code and replace it with code to attack the root drivers of what are today incurable diseases. Essentially this creates a "stealth bomber" benevolent virus in your body. The future of this treatment could "send radiation and chemotherapy the way of bloodletting and leeches" as Jeff says in this podcast. Jeff has a contagious energy for gene technology and a grand vision of the future of curing the incurable.If you want to get a peak at how gene technology could quite literally change the world (and soon!) listen to what Jeff has to say.Enjoy!About Jeff GalvinJeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.Show notes:Jeff's LinkedInJeff on Twitter: @jeffreygalvinhttps://www.americangene.com/Press Release about AGT's FDA approval to continue HIV cure programAGT on LinkedInAGT on Twitter - @americangeneAGT on Facebook - @amerigeneAGT on Instagram - @americangenetechnologiesMusic by keldezQualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

Episode metadata supplied by the publisher feed · Published Mar 25, 2021

Embed this episode

What if incurable diseases like HIV, cancer, PKU, and epithelial solid tumors were completely curable? We're closer than you might think. Really close. In fact, Jeff Galvin and his team at American Gene Technologies™ (AGT) have been advancing the research and application of viral vectors for several years with some incredibly exciting breakthroughs on the horizon (hint: curing HIV could be just a few years away). In case you didn't know already, viral vectors is a relatively new t...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Curing Incurable Diseases with Jeff Galvin of American Gene Technologies

0:00 26:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of From Lab to Launch by Qualio?

This episode is 26 minutes long.

When was this From Lab to Launch by Qualio episode published?

This episode was published on March 25, 2021.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this From Lab to Launch by Qualio episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!